# Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

> **NCT00500500** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 40 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** EGb 761® (Tanakan®)

## Key facts

- **NCT ID:** NCT00500500
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Inability to recruit sufficient number of patients
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500500, "Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00500500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*